

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA



Scan this QR to view the Prospectus

Corporate Identification Number: U21001MH2024PLC421713

Our Company was originally formed as a partnership firm under the name and style of “M/s. Vijay Pharma” pursuant to a deed of partnership dated October 05, 1971, as amended from time to time. Further, M/s. Vijay Pharma was converted into a public limited company “VijayPD Ceutical Limited” pursuant to the provisions of Chapter XXI of the Companies Act, 2013 and a fresh Certificate of Incorporation dated March 19, 2024, was issued by Assistant Registrar of Companies, Central Registration Centre. Further our Company has acquired the running business of M/s. P.D. Doshi, a Partnership firm on going concern basis vide Business Transfer Agreement dated April 01, 2024 entered by and between Samit Madhukar Shah, Rahul Jitendra Shah, Jigar Narendra Shah, Bhavin Dhirendra Shah, Dhirendra Chimanlal Shah and Nila Narendra Shah, on behalf of M/s. PD. Doshi, Partnership firm and our company. The Corporate Identification Number of our Company is U21001MH2024PLC421713. For further details on Incorporation and Registered Office of our Company, see “History and Certain Corporate Matters” beginning on page 177 of the Prospectus.

Registered Office: A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai – 400062, Maharashtra, India.

Contact Person: Madhuri Ganesh Batwal, Company Secretary & Compliance Officer

Tel: +91 9820917040 | E-mail: investors@vijaypdceutical.com | Website: www.vijaypdceutical.com | CIN: U21001MH2024PLC421713

THE PROMOTERS OF OUR COMPANY ARE SAMIT MADHUKAR SHAH, BHAVIN DHIRENDRA SHAH, RAHUL JITENDRA SHAH, NARENDRA NAGINDAS SHAH, DINA MADHUKAR SHAH, VASANTI DHIRENDRA SHAH AND HEMANTI JITENDRA SHAH

“THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS, 2018 (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (NSE EMERGE).”

## THE ISSUE

INITIAL PUBLIC OFFER OF 55,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE “EQUITY SHARES”) OF VIJAYPD CEUTICAL LIMITED (“OUR COMPANY” OR “VIJAYPD” OR “THE ISSUER”) FOR CASH AT A PRICE OF ₹ 35/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 25/- PER EQUITY SHARE (THE “ISSUE PRICE”) AGGREGATING TO ₹ 1,925.00 LAKHS (“THE ISSUE”), OF WHICH 2,84,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 35/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 25/- PER EQUITY SHARE AGGREGATING TO ₹ 99.40 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e., NET ISSUE OF 52,16,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 35/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 25/- PER EQUITY SHARE AGGREGATING TO ₹ 1,825.60 LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.16% AND 26.71% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ISSUE PRICE: ₹ 35/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

THE ISSUE PRICE IS 3.5 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2024-25 AT THE ISSUE PRICE IS 9.11.

APPLICATIONS CAN BE MADE FOR A MINIMUM OF 8,000 EQUITY SHARES AND IN MULTIPLES OF 4,000 EQUITY SHARES THEREAFTER.

## ISSUE PROGRAM

OPENS ON : MONDAY, SEPTEMBER 29, 2025

CLOSES ON : WEDNESDAY, OCTOBER 01, 2025

We are engaged in the business of distribution and supply within the pharmaceutical and consumer goods sectors, offering a comprehensive range of services. Our roles include being representatives, dealers, agents, stockists, suppliers, traders, and packers. We offer a wide range of products serving both the pharmaceutical and wellness industries, as well as the fast-moving consumer goods (FMCG) market. Our pharmaceutical and wellness product range includes medicines such as injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral formulations. We also supply vitamins, hormones, enzymes, wellness tonics, serums, and diagnostic test kits. In the FMCG segment, we provide personal care and toiletry products, including soaps, sanitizers, and baby care items. Additionally, we deal in ayurvedic products, cosmetics, food products, dental products, and crude drugs. For more details, please refer chapter titled “Our Business” beginning on page 151 of the Prospectus.

THE EQUITY SHARES OF THE COMPANY ISSUED THROUGH THE PROSPECTUS ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE. FOR THE PURPOSE OF THE OFFER, THE DESIGNATED STOCK EXCHANGE SHALL BE NSE EMERGE.

## ALLOCATION OF THE ISSUE

INDIVIDUAL INVESTOR PORTION	26,08,000 Equity Shares of ₹ 10/- each
OTHER THAN INDIVIDUAL PORTION	26,08,000 Equity Shares of ₹ 10/- each
MARKET MAKER PORTION	2,84,000 Equity Shares of ₹ 10/- each

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE PROSPECTUS AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER.

The Issue Price as determined by our Company in consultation with Lead Manager and as stated under “Basis for Issue Price” beginning on page 103 of the Prospectus.

### RISKS TO INVESTORS

1. Risk to Investors: Summary description of key risk factors based on materiality:

- Our company is positioning itself to expand its market presence by diversifying into the manufacturing of Active Pharmaceutical Ingredients (“APIs”), which serve as raw materials for the formulation of various types of Finished Dosage Forms (“FDF”) and Excipients. However, this expansion may expose us to several risks that could adversely affect our growth, prospects, cash flows, business operations, and financial condition.
- We may incur losses, and our reputation may be adversely affected if customers return our products due to the distribution of expired, unsafe, defective, ineffective, or counterfeit products, as well as product spoilage, breakage, or damage during transportation or storage. Failure to comply with customer-prescribed quality standards may also result in loss of business. In addition, we may be subject to product liability claims.
- We derive a significant portion of our revenue from customers located in Maharashtra. Any adverse developments in the region could adversely affect our business, results of operations, cash flows and financial condition.
- Our Company is reliant on the demand from the pharmaceutical industry for a significant portion of our revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage our sales could have an adverse impact on our Company's business and results of operations.
- Since our inception, we have completed one of the acquisitions of distributors in India to expand our business and increase our customer base and may continue to complete more acquisitions in the future. However, we may be unable to realize the anticipated benefits of past or future acquisitions successfully. Further, if we are unable to identify expansion opportunities or experience delays or other problems in implementing our strategy of inorganic growth, our business, financial condition, results of operations, cash flows and prospects may be adversely affected.
- We procure a significant portion of our raw materials from suppliers based in the State of Maharashtra. Any adverse developments in the region could adversely affect our business, results of operations, cash flows and financial condition.
- We do not have long term agreements with our customers, which could adversely impact our business as our customers can terminate their relationships with us without notice.

2. Details of suitable ratios of the company and its peer group for the latest full financial year:

Name of Company	CMP (₹)	Face Value (₹)	Basic & Diluted EPS (₹)	PE Ratio (times)	RoNW (%)	NAV per Share (₹)
Vijaypd Ceutical Limited	35.00	10	3.84	9.11	14.91%	25.78
Peer Group						
MedPlus Health Services Limited	840.55	2	3.37	249.42	3.32	103.63
Entero Healthcare Solutions Limited	1129.70	10	4.41	256.17	1.17	379.33

Source: www.bseindia.com, www.nseindia.com,

- Notes:**
- The figures for our company are based on Restated Financial Statements for the year ended March 31, 2025, after considering the bonus issue.
  - P/E Ratio has been computed based on their respective closing market price on September 19, 2025, as divided by the Basic EPS as on March 31, 2025.
  - Restated Profit for the year attributable to equity shareholders divided by Net Worth of our Company.
  - Net asset value per equity share is calculated as net worth as of the end of relevant year divided by the weighted average number of equities shares outstanding at the end of the year.
  - Price Earning (P/E) Ratio in relation to the Issue Price of ₹ 35/- per share.
  - The face value of our share is ₹ 10/- per share and the Issue Price is of ₹ 35/- per share are 3.5 times of the face value.
  - The peer group companies are not exactly comparable in all aspects of business and services that our Company provides.
  - Weighted Average Return on Net worth for the last 3 financial years (RoNW)**  
As per Restated Financial Statements

Particulars	RoNW (%)	Weights
March 31, 2025	14.91	3
March 31, 2024	165.02	2
March 31, 2023	3.68	1
Weighted Average	63.08%	

Note: Return on Net Worth (%) = Profit for the period / year / Net Worth at the end of the period / year.

4. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI:

a) The price per share of our Company based on the primary/ new issue of shares (equity / convertible securities), excluding shares issued under ESOP/ ESOS and issuance of bonus shares

Except as mentioned below, there have been no primary issuances of Equity Shares or convertible securities, excluding shares issued under employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of this Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid - up share capital of the Company (calculated based on the pre - Issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days:

Date of Allotment	No. of Equity Shares Allotted	Face Value (₹)	Issue Price (₹)	Nature of Consideration	Nature of Allotment	Amount (₹ in Lakhs)
Upon Incorporation dated March 19, 2024	10,00,000	10/-	10/-	Cash - against the outstanding Credit Balance of respective Individual Partner's Fixed Capital Account	Subscription to MOA	100.00
June 25, 2024	46,00,693	10/-	44.38/-	Other than Cash	Conversion of Loan to Equity Shares	2,041.79
July 29, 2024	14,13,650	10/-	44.38/-	Other than Cash	Pursuant to Business Takeover of M/s. PD Doshi, Partnership firm	627.38
Weighted Average cost of Primary Transactions						39.48

b) The price per share of our Company based on the secondary sale / acquisition of shares (equity shares)

Except as mentioned below, there have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre- issue share capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Sr. No	Name of Shareholder	Date of Transaction	Promoter / Promoter Group / Director	Number of Equity Shares Subscribed to / Acquired	Acquisition Price	Amount (₹ in Lakhs)
1.	Narendra Nagindas Shah	November 21, 2024	Promoter	6,33,012	41.00	259.53
2.	Hemanti Jitendra Shah	November 11, 2024	Promoter Group	5,76,018	41.00	236.17
3.	Vasanti Dhirendra Shah	November 13, 2024	Promoter	2,92,914	41.00	120.09
4.	Chandrika Dilipkumar Shah	November 18, 2024	Promoter Group	69,000	41.67	28.75
5.	Saroj Narendra Shah	November 18, 2024	Promoter Group	39,000	39.62	15.45
6.	Kusum Jitendra Shah	November 13, 2024	Promoter Group	2,34,000	41.00	95.94
7.	Jigar Narendra Shah	May 28, 2025	Promoter Group	9,84,000	3.56	35.03
Weighted Average Cost of Acquisition for Secondary Transactions						27.97

c) Since there is an eligible transaction of our Company reported in (a) & (b) above in accordance with paragraph (9)(K)(4)(a) of the SEBI ICDR Regulations therefore, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoters/Promoter Group entities or Shareholder(s) having the right to nominate director(s) on the Board are a party to the transaction) not older than three years prior to the date of this Draft Prospectus, irrespective of the size of transactions, has not been computed.

d) Weighted average cost of acquisition (“WACA”) and Issue price:

Weighted average cost of acquisition of Equity Shares based on primary/ secondary transaction(s), as disclosed in paragraph above, are set out below:

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)*	Issue Price (₹ 35.00) being ‘X’ times of WACA
Weighted average cost of acquisition of primary issuances as per paragraph (a) above	39.48	0.89
Weighted average cost of acquisition for secondary transactions as per paragraph (b) above	27.97	1.25

\*As certified by M/s. JD Shah & Associates, Chartered Accountants, by way of their certificate dated June 30, 2025.

### ADDITIONAL INFORMATION FOR INVESTORS:

- Details of proposed / undertaken pre-issue placements from the DP filing date** - Our Company has not undertaken any Pre-IPO Placements from the DP filing date.
- Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DP filing date** - Our promoter(s) and promoter group(s) have not undertaken any transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company from the DP filing date other than as mentioned below:

Name of Shareholder	Date of Transaction	Promoter / Promoter Group / Director	Number of Equity Shares Subscribed to/ Acquired	Number of Equity Shares Sold	Subscribed/ Acquired/ Transferred
Jigar Narendra Shah	September 10, 2025	Promoter Group	-	5,00,000	Transfer to Yash Hitesh Patel

3. Pre-Issue Shareholding of Promoter and Promoter Group:

Category of Promoter	Pre-Offer shareholding as at the date of Advertisement		Post-Issue shareholding as at Allotment	
	No. of Shares	% of Pre-Issue Capital	No. of Shares	% of Post-Issue Capital
<b>Promoters</b>				
Vasanti Dhirendra Shah	32,16,644	22.93%	32,16,644	16.47%
Dina Madhukar Shah	16,78,706	11.97%	16,78,706	8.60%
Bhavin Dhirendra Shah	16,36,094	11.66%	16,36,094	8.38%
Narendra Nagindas Shah	15,90,610	11.34%	15,90,610	8.14%
Hemanti Jitendra Shah	10,61,846	7.57%	10,61,846	5.44%
Samit Madhukar Shah	882,872	6.29%	882,872	4.52%
Rahul Jitendra Shah	0.00	0.00%	0.00	0.00%
<b>Promoters Group</b>				
Jigar Narendra Shah	4,84,000	3.45%	4,84,000	2.48%
Kusum Jitendra Shah	2,34,000	1.67%	2,34,000	1.20%
Nila Narendra Shah	91,914	0.66%	91,914	0.47%
Chandrika Dilipkumar Shah	69,000	0.49%	69,000	0.35%
Saroj Narendra Shah	39,000	0.28%	39,000	0.20%
<b>Total</b>	<b>1,09,84,686</b>	<b>78.30%</b>	<b>1,09,84,686</b>	<b>56.25%</b>

All Equity Shares held by the Promoters have been dematerialized as on date of this Prospectus.

(Continued next page...)



BASIS FOR ISSUE PRICE

The “Basis for Issue Price” on page 103 of the Prospectus has been updated. Please refer to the website of the Lead Manager for the “Basis for Issue Price” updated with the above price band. You can scan the QR code given on the first page of this Advertisement for the chapter titled “Basis for Issue Price” on page 103 of the Prospectus.

INDICATIVE TIMELINES FOR THE ISSUE

An indicative timetable in respect of the Issue is set out below:

Event	Indicative Date
Issue Opens on	Monday, September 29, 2025
Issue Closes on	Wednesday, October 01, 2025
Finalization of Basis of Allotment with the Designated Stock Exchange	On or before Friday, October 03, 2025
Initiation of Refunds / unblocking of funds from ASBA Account	On or before Monday, October 06, 2025
Credit of Equity Shares to demat account of the Allottees	On or before Monday, October 06, 2025
Commencement of trading of the Equity Shares on the Stock Exchange	Tuesday, October 07, 2025

Sequence of Activities	Listing within T+3 days (T is Issue Closing Date)
Application Submission by Investors	Electronic Applications (Online ASBA through 3-in-1 accounts) – Up to 5 pm on T Day. Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc) – Up to 4 pm on T Day. Electronic Applications (Syndicate Non-Institutional, Non-Individual Applications) – Up to 3 pm on T Day. Physical Applications (Bank ASBA) – Up to 1 pm on T Day. Physical Applications (Syndicate Non-Institutional, Non- Individual Applications of QIBs and NIIs) – Up to 12 pm on T Day and Syndicate members shall transfer such applications to banks before 1 pm on T Day.
Validation of bid details with depositories	From Issue opening date up to 5 pm on T Day
Reconciliation of UPI mandate transactions (Based on the guidelines issued by NPCI from time to time): Among Stock Exchanges – Sponsor Banks – NPCI and NPCI – PSPs/TPAPs** – Issuer Banks; Reporting formats of bid information, UPI analysis report and compliance timelines.	On Daily basis  Merchant Bakers to submit to SEBI, sought as and when.
UPI Mandate acceptance time	T day – 5 pm
Issue Closure	T day – 4 pm for QIB and NII categories T day – 5 pm for II and other reserved categories
Third party check on UPI applications	On daily basis and to be completed before 9:30 AM on T+1 day.
Third party check on Non-UPI applications	On daily basis and to be completed before 1 pm on T+1 day.
Submission of final certificates: -For UPI from Sponsor Bank -For Bank ASBA, from all SCSBs -For syndicate ASBA	UPI ASBA – Before 9:30 pm on T Day. All SCSBs for Direct ASBA – Before 07:30 pm on T Day. Syndicate ASBA - Before 7:30 pm on T Day.
Finalization of rejections and completion of basis	Before 6 pm on T+1 day.
Approval of basis by Stock Exchange	Before 9 pm on T+1 day.
Issuance of fund transfer instructions in separate files for debit and unblock. For Bank ASBA and Online ASBA – To all SCSBs For UPI ASBA – To Sponsor Bank	Intimation not later than 9:30 am on T+2 day. Completion before 2 pm on T+2 day for fund transfer; Completion before 4 pm on T+2 day for unlocking
Corporate action execution for credit of shares	Initiation before 2 pm on T+2 day Completion before 6 pm on T+2 day
Filing of Listing Application with Stock Exchanges and issuance of trading notice	Before 7:30 pm on T+2 day
Publish allotment advertisement	On the website of Issuer, Merchant Banker and RTI - before 9 pm on T+2 day. In newspapers - on T+3 day but not later than T+4 day
Trading starts	T+3 day

**CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS:** For information on the main objects of our Company, see “History and Certain Corporate Matters” on page 177 of the Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section “Material Contracts and Documents for Inspection” on page 356 of the Prospectus.

**LIABILITY OF MEMBERS AS PER MOA:** The Liability of the members of the Company is Limited.

**AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE:** The authorized share capital of the Company is ₹ 20,00,00,000 divided into 2,00,00,000 Equity Shares of ₹ 10/ each. The issued, subscribed and paid-up share capital of the Company before the Issue is ₹ 14,02,86,860 divided into 1,40,28,686 Equity Shares of ₹ 10/ each. For details of the Capital Structure, see “Capital Structure” on the page 73 of the Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:

ORIGINAL SIGNATORIES			CURRENT PROMOTERS		
Name of Promoters	Face Value (₹)	No. of Shares	Name of Promoters	Face Value (₹)	No. of Shares
Vasanti Dhirendra Shah	10.00	250,000	Vasanti Dhirendra Shah	10.00	32,16,644

Narendra Nagindas Shah	10.00	1,80,000	Dina Madhukar Shah	10.00	16,78,706
Jigar Narendra Shah	10.00	1,50,000	Bhavin Dhirendra Shah	10.00	16,36,094
Hemanti Jitendra Shah	10.00	1,30,000	Narendra Nagindas Shah	10.00	15,90,610
Bhavin Dhirendra Shah	10.00	90,000	Hemanti Jitendra Shah	10.00	10,61,846
Samit Madhukar Shah	10.00	90,000	Samit Madhukar Shah	10.00	882,872
Dina Madhukar Shah	10.00	80,000	Rahul Jitendra Shah	10.00	0
Rahul Jitendra Shah	10.00	30,000	NA		

**LISTING:** The Equity Shares issued through the Prospectus are proposed to be listed on the SME Platform of NSE (“NSE Emerge”). Our Company has received an “In-principle” approval from the NSE for the listing of the Equity Shares pursuant to letter dated September 02, 2025. For the purposes of the Issue, the Designated Stock Exchange shall be NSE. A signed copy of the Prospectus has been submitted for registration to the ROC on September 22, 2025 and Prospectus shall be filed with the RoC in accordance with Section 26(4) of the Companies Act, 2013.

**DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”):** Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire “Disclaimer Clause of SEBI” beginning on page 280 of the Prospectus.

**DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE):** It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE, nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the “Disclaimer Clause of NSE” beginning on page 283 of the Prospectus.

**GENERAL RISK:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 31 of this Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>SMART HORIZON CAPITAL ADVISORS PRIVATE LIMITED</b> (Formerly Known as Shreni Capital Advisors Private Limited) B/908, Western Edge II, Kanakia Space, Behind Metro Mall, off Western Express Highway, Magathane, Borivali East, Mumbai – 400066, Maharashtra, India. <b>Tel. No.:</b> 022-28706822 <b>E-mail:</b> director@shcapl.com <b>Investors Grievance e-mail:</b> investor@shcapl.com <b>Contact Person:</b> Mr. Parth Shah <b>Website:</b> www.shcapl.com <b>SEBI Registration Number:</b> INM000013183	 <b>KFIN TECHNOLOGIES LIMITED</b> Selenium Tower-B Plot No. 31 & 32 Gachibowli, Financial District, Nan akramguda Serilingampally, Hyderabad - 500032, Telangana, India <b>Telephone:</b> +91 40 6716 2222 <b>Email:</b> vcl ipo@kfintech.com <b>Website:</b> www.kfintech.com <b>Investors Grievance e-mail:</b> einward.ris@kfintech.com <b>Contact person:</b> M. Murali Krishna <b>SEBI Registration Number:</b> INR000000221	 <b>Madhuri Ganesh Batwal</b> Company Secretary and Compliance Officer. <b>Address:</b> A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai – 400062, Maharashtra, India   <b>Tel. No.:</b> +91-9820917040 <b>Email:</b> investors@vijaypdceutical.com <b>Website:</b> www.vijaypdceutical.com  Investors can contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or post- issue related grievances, grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all issue related queries and for redressal of complaints, investors may also write to the LMs.

**AVAILABILITY OF PROSPECTUS:** Investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the issue. Full copy of the Prospectus will be available at the website of SEBI at www.sebi.gov.in; the website of Stock Exchange at https://www.nseindia.com/, the website of LM at www.shcapl.com and website of Company at www.vijaypdceutical.com.

**AVAILABILITY OF APPLICATION FORMS:** Application forms can be obtained from the Company: Vijaypd Ceutical Limited, Lead Manager: Smart Horizon Capital Advisors Private Limited. Application Forms can also be obtained from the Stock Exchange and list of SCSBs available on the website of SEBI at www.sebi.gov.in and website of Stock Exchange at https://www.nseindia.com/

**APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA):** All investors in this issue have to compulsorily apply through ASBA. The investors are required to fill the ASBA form and submit the same to their banks. The SCSB will block the amount in the account as per the authority contained in ASBA form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund.

For more details on the issue process and how to apply, please refer to the details given in application forms and abridged prospectus and also please refer to the chapter “Issue Procedure” on page 303 of the Prospectus

**BANKER TO THE ISSUE:** Kotak Mahindra Bank Limited

**UPI:** UPI Applicants can also apply through UPI mechanism

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

For VIJAYPD CEUTICAL LIMITED

Sd/-

Samit Madhukar Shah

Designation: Chairman & Managing Director

DIN: 09634053

Date: September 23, 2025

Place: Mumbai

**Vijaypd Ceutical Limited** is proposing, subject to market conditions and other considerations, Public Issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Mumbai on September 22, 2025. The Prospectus is available on the website of the Lead Manager at www.shcapl.com, the website of the NSE i.e., https://www.nseindia.com/, and website of our Company at www.vijaypdceutical.com.

Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Prospectus, including the section titled “Risk Factors” of the Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the U.S. Securities Act (“the Securities Act”) or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as defined in Regulations under the securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.